NASDAQ · Biotechnology

Kiniksa Pharmaceuticals International, plc (KNSA) Stock

$76.73 -5.03% NASDAQ: KNSA Healthcare

Valuation

MetricValue
Price$76.73
Market Cap$5.99B
P/E Ratio70.83
P/B Ratio8.99
P/S Ratio6.87
EPS (TTM)$0.75
52-Week High$83.17
52-Week Low$35.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE13.65%
ROA9.00%
ROCE13.83%
Gross Margin11.50%
Operating Margin11.36%
Net Margin9.59%
Debt/Equity0.01
Current Ratio3.79

Annual Financials (USD)

Metric20212022202320242025
Revenue$39.0M$220.0M$270.0M$423.0M$678.0M
Operating Profit$-157.0M$10.0M$-25.0M$-46.0M$77.0M
Net Profit$-158.0M$183.0M$14.0M$-43.0M$59.0M
EPS$-2.30$2.60$0.20$-0.60$0.75
Op Margin-406.4%4.4%-9.3%-10.8%11.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$233.0M$460.0M$526.0M$581.0M$764.0M
Total Liabilities$48.0M$64.0M$87.0M$142.0M$196.0M
Cash$122.0M$123.0M$108.0M$184.0M$166.0M
Borrowings$6.0M$6.0M$12.0M$10.0M$9.0M

Latest News

Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In? Simply Wall St. · Jul 9, 2026 Axsome Begins Phase III Study on Solriamfetol for ADHD in Children Zacks · Jul 8, 2026 AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up Zacks · Jul 8, 2026 Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue? Zacks · Jul 8, 2026 Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why Zacks · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-126.0M$6.0M$13.0M$26.0M$26.0M
Investing Cash Flow$108.0M$-8.0M$-30.0M$37.0M$37.0M
Financing Cash Flow$0$-1.0M$1.0M$12.0M$12.0M
Net Cash Flow$8.0M$0$-15.0M$76.0M$76.0M
Free Cash Flow$-147.0M$6.0M$13.0M$25.0M$25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA50.04
FCF Yield3.17%
Quick Ratio3.49
Interest Coverage—
Return 1Y119.40%
Return 3Y361.01%
Return 5Y548.46%

Ownership

Insiders Held3.58%
Institutions Held102.50%
Institutions Float Held106.31%
Institutional HolderSharesReport Date
FMR, LLC6,823,7002026-03-31
Rubric Capital Management LP3,750,0002026-03-31
Baker Bros. Advisors, LP2,826,2462026-03-31
Tang Capital Management, LLC2,259,8892026-03-31
Vanguard Portfolio Management LLC1,766,2682026-03-31

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc (KNSA) stock trades at $76.73 with a market capitalization of $5.99B. The stock is valued at a price-to-earnings (P/E) ratio of 70.83, price-to-book of 8.99, price-to-sales of 6.87. Over the past 52 weeks the stock has ranged between $35.20 and $83.17, and currently trades 7.7% below its 52-week high.

On profitability, Kiniksa Pharmaceuticals International, plc generates a return on equity (ROE) of 13.65%, return on capital employed of 13.83%, an operating margin of 11.36%, a net profit margin of 9.59%.

Kiniksa Pharmaceuticals International, plc by the numbers, 2016–2025

Between 2016 and 2025 Kiniksa Pharmaceuticals International, plc reported revenue of $0 rising to $678.0M. Compounded, revenue has grown —% a year over five years, 45.5% over three, 60.3% over the last twelve months. Net profit rose to $59.0M.

The most recent net margin is 9.59%. On a trailing twelve-month basis to Jun '26, revenue is $841.0M and net profit $80.0M.

Borrowings stand at $9.0M, cash from operations was $26.0M in the latest year, positive in 4 of the last 10.

Return on equity has averaged -7.1% over five years, and was 10.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Kiniksa Pharmaceuticals International, plc (KNSA) — frequently asked questions

What is Kiniksa Pharmaceuticals International, plc (KNSA) stock price today?

Kiniksa Pharmaceuticals International, plc (KNSA) is currently trading at $76.73, down 5.03% today.

What is KNSA P/E ratio?

Kiniksa Pharmaceuticals International, plc's P/E ratio is 70.83. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.

What is KNSA return on equity (ROE)?

Kiniksa Pharmaceuticals International, plc's return on equity (ROE) is 13.65%. ROE measures net income relative to shareholders' equity. This is within the typical market range of roughly 12-15%.

What is Kiniksa Pharmaceuticals International, plc's market cap?

Kiniksa Pharmaceuticals International, plc has a market capitalization of $5.99B.

Does KNSA pay a dividend?

Kiniksa Pharmaceuticals International, plc is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does KNSA carry?

Kiniksa Pharmaceuticals International, plc has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is KNSA's profit margin?

Kiniksa Pharmaceuticals International, plc reports a net profit margin of 9.59% — the share of revenue left after every cost, including tax and interest.

What sector is KNSA in?

Kiniksa Pharmaceuticals International, plc is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is KNSA listed on?

Kiniksa Pharmaceuticals International, plc trades on NASDAQ under the ticker KNSA.

What is KNSA's 52-week range?

Over the last year Kiniksa Pharmaceuticals International, plc has traded between $35.20 and $83.17.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens KNSA currently matches

On the figures above, Kiniksa Pharmaceuticals International, plc passes the filters for 10 of our ready-made screens, among them Low Debt Stocks, Day Losers Stocks, Healthcare Stocks To Buy. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksDay Losers StocksHealthcare Stocks To BuyDebt Free Stocks Under $100High PE StocksDebt Free StocksStocks Under $100Mid Cap StocksDebt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.